Neuroendocrine tumors of the small bowels are on the rise: Early tumors and their management;Neuroendokrine tumoren des dünndarms nehmen zu: Frühe tumoren und deren management

Zeitschrift fur Gastroenterologie

Volumn 48, Issue 3, 2010, Pages 406-413

  Scherubl H ^a   Schwertner, C ^a   Steinberg, J ^a   Stolzel U ^b   Pohl, J ^c   Dralle, H ^d   Kloppel G ^e  

^a VIVANTES KLINIKUM AM URBAN   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Carcinoid; Carcinoma; Duodenum; Gastrinoma; Ileum

Indexed keywords

SOMATOSTATIN DERIVATIVE;

ADULT; CANCER STAGING; CARCINOID SYNDROME; CASE REPORT; DIAGNOSTIC PROCEDURE; DUODENUM; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC SURGERY; GASTRINOMA; HUMAN; ILEUM; METASTASIS; NEUROENDOCRINE TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SMALL INTESTINE; TUMOR LOCALIZATION; TUMOR VOLUME; UNITED STATES;

HUMANS; INCIDENCE; INTESTINAL NEOPLASMS; INTESTINE, SMALL; NEUROENDOCRINE TUMORS;

EID: 77749342632     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109862     Document Type: Review

References (43)

1. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
2. Yao J, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
3. Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-2664
4. Hassan MM, Phan A, Li D et al. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer 2008; 123: 867-873
5. Jensen RT, Niederle B, Mitry E et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinoloy 2006; 84: 173-182
6. Jensen RT, Rindi G, Arnold R et al. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinoloy 2006; 84: 165-172
7. Eriksson B, Klöppel G, Krenning E et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuoendocrinology 2008; 87: 8-19
8. Scherübl H, Faiss S, Zeitz M. Neuroendokrine gastrointestinale Tumore. Diagnostik und Therapie. Dtsch MedWochenschr 2003; 128: S81-S83
9. Zar N, Garmo H, Holmberg L et al. Long-term survival of patients with small intestinal carcinoid tumors. World J Surgery 2004; 28: 1163-1168
10. Bilimoria KY, Bentrem DJ, Wayne JD et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surgery 2009; 249: 63-71
11. Modlin I, Lye K, Kidd M. A 5-decade analysis of 13715 carcinoid tumors. Cancer 2003; 97: 934-959
12. Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009; 89: 471-476
13. Ito T, Tanaka M, Sasano H et al. The neuroendocrine tumor workshop of Japan. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007; 42: 497-500
14. Ahlman H, Nilsson O, McNicol AM et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008; 87: 40-46
15. Grabowski P, Scherübl H. Expression of neuroendocrine markers in undifferentiated carcinomas of the gastrointestinal tract. J Clin Oncol 2005; 23: 4795-4797
16. Solcia E, Klöppel G, Sobin LH. (in collaboration with 9 pathologists from 4 countries). Histological typing of endocrine tumours. Second Edition. WHO international histological classification of tumours. Berlin: Springer, 2000
17. Klöppel G, Heitz PU, Capella C et al. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions.World J Surg 1996; 20: 132-141
18. Klöppel G, Rindi G, Anlauf Met al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451 Suppl 1: S9-S27
19. Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401
20. Rindi G, Klöppel G, Couvelard A et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762
21. Soga J. Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J Exp Clin Cancer Res 2003; 22: 349-363
22. Soga J. Early-stage carcinoids of the gastrointestinal tract: An analysis of 1914 reported cases. Cancer 2005; 103: 1587-1595
23. Modlin IM, Champaneria MC, Chan AK et al. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastro 2007; 102: 1464-1473
24. Scherübl H, Schaaf L, Raue F et al. Hereditäre neuroendokrine gastroenteropankreatische Tumore und multiple endokrine Neoplasie Typ1. Aktuelle Diagnostik und Therapie. Dtsch MedWochenschr 2004; 129: 630-633 und 689 - 692
25. Scherübl H, Faiss S, Tschöpe R et al. Double-balloon enteroscopy for the detection of midgut carcinoids. Gastrointest Endosc 2005; 62: 994-995
26. Scherübl H. Options for gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 203
27. Zimmer T, Scherübl H, Faiss S et al. Endoscopic ultrasonography of neuroendocrine tumours. Digestion 2000; 62: 45-50
28. Wiedenmann B, Bäder M, Scherübl H et al. Gastroenteropancreatic neuroendocrine tumor imaging with somatostatin-receptor scintigraphy. Sem Oncology 1994; 21: 29-32
29. Hoegerle S, Altehoefer C, Scherübl H et al.Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001; 220: 373-380
30. Koopmans K, Neels O, Kema I et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26: 1489-1495
31. Garbrecht N, Anlauf M, Schmitt A et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15: 229-241
32. Nilsson O, Van Cutsem E, Delle Fave G et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006; 84: 212-215
33. Shimizu N, Kaminishi M. Management of patients with neuroendocrine tumors of the esophagus, stomach, and duodenum. Nippon Geka Gakki Zasshi 2008; 109: 147-151
34. Eriksson J, Stålberg P, Nilsson A et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surgery 2008; 32: 930-938
35. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130
36. Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279
37. Steinmüller T, Kianmanesh R, Falconi M et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut,midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62
38. Swärd C, Johanson V, Nierveen van Dijkum E et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009; 96: 517-521
39. Arnold R, Müller H, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol 2009; 27: 4656-4663
40. Höpfner M, Schuppan D, Scherübl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterology 2008; 14: 2461-2473
41. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318
42. Yao JC, Phan A, Hoff PM et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323
43. Hosokawa O, Miyanaga T, Kaizaki Y et al. Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol 2008; 43: 1112-1115